Entries by immunocity

Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1b Clinical Trial in Melanoma

12 April 2023 in /by

Cambridge, UK, 12 April – Microbiotica, a leader in discovering and developing microbiome-based therapeutics and biomarkers, today announces it has entered into a clinical trial collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA). Under the terms of the agreement, Microbiotica will conduct a phase 1b clinical trial to evaluate the safety and tolerability, […]

Microbiotica announces transition of leadership

29 November 2022 in /by

Co-founder and CEO Mike Romanos steps down after six years to take up role of Associate Dean of Enterprise in the Faculty of Medicine at Imperial College Tim Sharpington, Microbiotica COO and experienced industry executive, appointed new CEO Cambridge, UK, 29 November 2022 – Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and […]

Microbiotica to present at key industry conferences in Q3 2022

20 June 2022 in /by

Cambridge, UK, 20 June 2022 – Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, confirms its upcoming scientific conference attendance. Microbiome Movement – Drug Development, 21-24 June 2022, Boston, US Dr Ron Carter, Microbiotica’s CMO, will be contributing to a panel at Microbiome Movement – Drug Development, taking place in Boston, […]